Shots:
The US FDA has granted BTD to ulixacaltamide for the treatment of patients with essential tremor (ET)
Designation was based on the topline data from the Essential3 program, consisting of Study 1 & 2, where in Study 1, ulixacaltamide improved mADL11 (1EP) by 4.3 points at Wk. 8, while Study 2 showed superior maintenance of…
